Nasal Spray Utilizing Needle-Free Technology
039 Kovanaze with Mike Smilanich, DDS
INDICATION: KOVANAZE is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 and A-J in adults and children who weigh 40 kg or more. Patients may not experience the same sensations of numbness or tingling of the lips and cheeks
associated with injectable anesthetics.
Kovanaze provides regional anesthesia with 96% efficacy in teeth #5-12, 64% in #4 and #13*, therefore Kovanaze offers a needle-free alternative to the majority of anterior maxillary injections.
Active Pharmaceutical Ingredients (APIs)Kovanaze® is comprised of two well-known and well-established pharmaceuticals administered as a nasal spray.
Tetracaine hydrochloride, the active pharmaceutical, is an ester local anesthetic that blocks sodium ion channels required for the initiation and conduction of neuronal impulses. Oxymetazoline hydrochloride is a sympathomimetic that exerts its local decongestant effects in the nose by stimulating adrenergic receptors, thus eliciting vasoconstriction of dilated arterioles and reducing nasal blood flow.
Dr. Smilanich received his DDS from the University of Minnesota in 1983 and maintains a private practice in Minneapolis Minnesota where he is the director of the Minneapolis Implant Institute. For over thirty years he has successfully restored thousands of implants and in1992 he became one of the first doctors to be accredited by the Academy of Osseointegration. His work with innovative prosthetic systems, immediate fixed provisionalization, and restoring collapsed vertical dimension in cases of bruxism and parafunction has been shared with colleagues in didactic lectures as well as hands on, workshop, and residency formats. Dr. Smilanich’s candid evaluation of what techniques are the simplest, most predictable, and most profitable in real time private practice, have made him a popular speaker on restorative techniques for over 25 years. He also serves as a consultant for several laboratory, biomedical, and pharmaceutical companies and continues to contribute to innovation in the field of implant rehabilitation.